Summer 2018 | Live Blog | Product Theater | Tremfya: A Selective IL-23 Inhibitor with Pivotal Studies vs. Adalimunab
June 28, 2018For the first product theater of the SDPA Annual Summer Conference, Cynthia Trickett, PA-C, reviewed Tremfya. Ms. Trickett specializes in the treatment of patients with psoriatic disease and discussed Tremfya as a first line therapy medication for patients 18 years or older with moderate to severe plaque psoriasis. As Ms. Trickett stated, “psoriasis affects and …